Average Al is a wealth of information... The pseudo expert.
Allogene are nearly 12 months into their P2 trial. By the time Azercel progresses to P2, Allogene will be 2 years ahead and targeting the larger LBCL patient population. And that's only if IMU find the cash to fund it.
IMU Price at posting:
2.6¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)